Comparison of Efficacy And Safety Silodosin 8 Mg Once Daily And Silodosin 4 Mg Twice Daily in BPH Patients With Luts

Ramzie Nendra Diansyah and Johan Renaldo and Wahjoe Djatisoesanto, NIDN. 8826900016 and Lukman Hakim, NIDN. 0009087302 (2019) Comparison of Efficacy And Safety Silodosin 8 Mg Once Daily And Silodosin 4 Mg Twice Daily in BPH Patients With Luts. Indonesian Journal of Urology, 26 (01). pp. 91-98. ISSN 0853-442X

[img] Text (Peer Review)
Comparison Of Efficacy And Safety.pdf

Download (2MB)
[img] Text (Artikel)
Comparison of Efficacy and Safety Silodosin_compressed.pdf

Download (10MB)
[img] Text (Similarity)
Comparison of Efficacy and Safety Silodosin 8 MG Once Daily and Silodosin 4 MG Twice Daily in BPH Patients With Luts.pdf

Download (4MB)
Official URL: https://juri.urologi.or.id/?journal=juri&page=arti...

Abstract

Objective: This study was aimed to compare the efficacy and side effect of silodosin 8mg once daily and silodosin 4mg twice daily in BPH-LUTS patients after 4 and 12 weeks. Material & Methods: Single blind randomized controlled trials in 60 male patients aged ≥45 years with BPH-LUTS from July 2017 to October 2017 was divided into groups who received 8mg of silodosin once daily and those who received 4mg of silodosin twice daily. Efficacy and adverse events were evaluated after 4 and 12 weeks of treatment. Results: There was no significant difference of mean age of the two groups was 67.93 ± 6.49 years and 69.07 ± 6.28 years respectively (p 0.49). Both doses of this drug decreased the International Prostate Symptom Score (IPSS) and significantly increased the maximum urinary flow (Qmax) (p<0.05) but there was no significant differences between the two groups (p>0.05). Ejaculation disorder was the most common side effect in all groups (6.7% and 5%) and there was no significant difference between the two groups (p>0.05). Conclusion: The administration of 8mg of once daily silodosin has similar efficacy as 4mg twice daily silodosin. There were no adverse events differences in the two groups. Ejaculation disorder is the most common adverse event of silodosin administration.

Item Type: Article
Uncontrolled Keywords: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms, International Prostate Symptom Score, Qmax, Ejaculation Disorder
Subjects: R Medicine > R Medicine (General)
R Medicine > RD Surgery > RD520-599.5 Surgery by region, system, or organ
Divisions: 01. Fakultas Kedokteran > Urologi
Creators:
CreatorsNIM/NIDN
Ramzie Nendra DiansyahUNSPECIFIED
Johan RenaldoUNSPECIFIED
Wahjoe Djatisoesanto, NIDN. 8826900016wahjoe.djatisoesanto@fk.unair.ac.id
Lukman Hakim, NIDN. 0009087302UNSPECIFIED
Depositing User: hanif kurniawan
Date Deposited: 19 Nov 2019 04:46
Last Modified: 19 Nov 2019 04:46
URI: http://repository.unair.ac.id/id/eprint/89631
Sosial Share:

Actions (login required)

View Item View Item